GenEditBio Receives RAISe+ Grant for Groundbreaking Human Genome Editing Initiative
June 11, 2025 |
AEF |
Portfolio
Share :
We are thrilled to share that our Co-Founder & Chairman, DrZongli Zheng, has been awarded the prestigious RAISe+ grant for his translational project entitled “In Vivo Somatic Human Genome Editing to Cure Genetic Diseases: Transforming Novel Genome Editors and Engineered Delivery Vehicles to Clinical Trial” under the Research, Academic and Industry Sectors One-plus (RAISe+) Scheme by theInnovation and Technology Commissionof the HKSAR Government via香港城市大學.
RAISe+ is the flagship funding initiative in Hong Kong to accelerate the transformation and commercialisation of R&D outcomes, bridging government, academia, industry, and investors. Applications are rigorously peer-reviewed for scientific excellence, team expertise, commercial potential, societal impact, and cost-effectiveness—making this a highly competitive and distinguished honour!
This esteemed recognition underscores the transformative potential of our pioneering work in advancing genome editing therapies from bench to bedside. Dr Zheng’s visionary leadership and unwavering dedication to tackling genetic diseases will pave the way for life-changing medical breakthroughs.
A very proud moment for our team at GenEditBio and the scientific community! At GenEditBio, we are committed to developing fundamentally safe, efficacious and affordable in vivo genome editing therapies for genetic diseases with unmet medical needs.
